BIM
GEVA

BlackRock Investment Management’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

BlackRock Investment Management’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-74,379
Closed -$7.25M – 4289
2015
Q1 		$7.25M Buy
74,379
+16,257
+28% +$1.72M 0.01% 1141
2014
Q4 		$5.39M Sell
58,122
-233
-0.4% -$18.4K 0.01% 1310
2014
Q3 		$4.01M Sell
58,355
-86
-0.1% -$6.16K 0.01% 1501
2014
Q2 		$6.13M Buy
58,441
+1,492
+3% +$127K 0.01% 1257
2014
Q1 		$4.72M Buy
56,949
+4,133
+8% +$382K 0.01% 1406
2013
Q4 		$3.42M Buy
52,816
+4,506
+9% +$267K 0.01% 1625
2013
Q3 		$3.06M Buy
48,310
+3,357
+7% +$165K 0.01% 1634
2013
Q2 		$1.89M Buy
+44,953
New +$2.05M ﹤0.01% 1897

BlackRock Investment Management's GEVA Position: Q2 2015 in Review

BlackRock Investment Management sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 74,379 shares — an estimated $7.25M sold.

BlackRock Investment Management first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $7.25M in Q1 2015. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • BlackRock Investment Management reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • BlackRock Investment Management sold 74,379 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $7.25M.
  • BlackRock Investment Management first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • BlackRock Investment Management's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $7.25M in Q1 2015.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on BlackRock Investment Management's 13F filing for Q2 2015, filed 7 Aug 2015.